文献速递药物不良反应与药物警戒

奥曲肽相关中性粒细胞减少症:一例病例报告

Octreotide-Associated Neutropenia.
PubMed 文献 · Pharmacotherapy · 2017-01-01

本文报告一例87岁男性结肠癌肠梗阻患者,在接受奥曲肽100 µg皮下注射每8小时一次、共3剂后立即出现中性粒细胞减少,停药后白细胞和中性粒细胞计数迅速恢复。Naranjo不良反应概率量表评分为5分,提示很可能与奥曲肽相关。这是首例奥曲肽相关中性粒细胞减少症的病例报告。

要点

  • 奥曲肽说明书目前未列中性粒细胞减少为不良反应,临床需警惕。
  • 用药后出现中性粒细胞减少应评估时间关联并考虑停药。
  • Naranjo评分5分提示很可能相关,停药后血象恢复支持判断。

核心结论

  • 本病例提示奥曲肽可能导致中性粒细胞减少,停药后血象迅速恢复。

研究设计与样本

  • 单例病例报告:87岁男性结肠癌肠梗阻患者,接受奥曲肽100 µg皮下注射每8小时一次。

主要发现

  • 入院时白细胞4.1×10^3/mm³(中性粒细胞75.4%,ANC 3.1×10^3/mm³)。
  • 接受3剂奥曲肽后第5天白细胞降至1.6×10^3/mm³(中性粒细胞62%,ANC 0.99×10^3/mm³)。
  • 停药后次日白细胞升至4.9×10^3/mm³(中性粒细胞66.3%,ANC 3.2×10^3/mm³)。
  • 30天后白细胞6.7×10^3/mm³(中性粒细胞83.2%,ANC 5.6×10^3/mm³)保持稳定。
  • Naranjo不良反应概率量表评分为5分,提示很可能相关。

临床怎么用

  • 使用奥曲肽期间应监测血常规,尤其出现感染征象时。
  • 怀疑奥曲肽相关中性粒细胞减少时应及时停药并复查血象。

局限性

  • 单例病例报告,不能确立因果关系或估计发生率。
  • 患者合并结肠癌及肠梗阻,可能存在其他混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-induced neutropenia and agranulocytosis are rare adverse events but can be fatal. Neutropenia can be induced by a myriad of drugs from almost every pharmacologic class. Octreotide is a somatostatin analog that has been used to treat variceal bleeding, acromegaly, and severe diarrhea associated with metastatic tumors, and to reduce symptoms in the setting of malignant bowel obstruction and pseudoobstruction. The most common adverse effects associated with octreotide include pain at the injection site and gastrointestinal effects such as loose stools, cramping, and nausea; neutropenia is not currently listed as an adverse effect of the drug. We describe the case of an 87-year-old man who developed neutropenia immediately after administration of three doses of subcutaneous octreotide. He presented to the hospital with a history of constipation and straining for 3 days. He was admitted, and laxatives, suppositories, and enemas were administered over the next 3 days to induce a bowel movement; however, they were ineffective. Bowel obstruction secondary to a mass was confirmed by computed tomography; the mass was eventually diagnosed as colon cancer. Octreotide 100 µg subcutaneously every 8 hours was started for the obstruction on the evening of hospital day 4. After the patient had received 3 doses of octreotide, his white blood cell count (WBC) had decreased from 4.1 × 103 /mm3 (neutrophils 75.4%, absolute neutrophil count [ANC] 3.1 × 103 /mm3 ) on admission to 1.6 × 103 /mm3 (neutrophils 62%, ANC 0.99 × 103 /mm3 ) on day 5. Given the temporal relationship of octreotide and neutropenia as well as the lack of a reasonable alternative cause, it was suspected that octreotide was the most likely culprit of the patient's neutropenia. Octreotide was subsequently discontinued, and his WBC increased to 4.9 × 103 /mm3 (neutrophils 66.3%, ANC 3.2 × 103 /mm3 ) the next day. The remainder of the patient's hospitalization was not significant for any further hematologic abnormalities. His WBC and ANC (WBC 6.7 × 103 /mm3 , neutrophils 83.2%, ANC 5.6 × 103 /mm3 ) remained stable 30 days after the incident. Use of the Naranjo Adverse Drug Reaction Probability Scale indicated a probable relationship (score of 5) between the patient's development of neutropenia and octreotide therapy. To our knowledge, this report highlights the first case of octreotide-associated neutropenia. Although the frequency of drug-induced neutropenia remains rare outside of cytotoxic chemotherapy, the importance of recognizing this adverse effect cannot be understated given the mortality risks for neutropenic patients.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Tse SS, Kish T. Octreotide-Associated Neutropenia. Pharmacotherapy. 2017. PMID: 28488730. doi:10.1002/phar.1942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。